Literature DB >> 1686385

Pleuropulmonary disease associated with dopamine agonist therapy.

M H Bhatt1, S P Keenan, J A Fleetham, D B Calne.   

Abstract

Artificial dopamine agonists are widely employed for the treatment of idiopathic parkinsonism. Pleuropulmonary disease has previously been reported to occur with the use of bromocriptine and mesulergine. We report similar adverse effects induced by the newer agonists lisuride and cabergoline. All these agents are tetracyclic ergot derivatives. This suggests a causal link between ergot-derived dopamine agonists and pleuropulmonary disease.

Entities:  

Mesh：

Substances：

Year:  1991        PMID： 1686385     DOI： 10.1002/ana.410300416

Source DB:  PubMed          Journal:  Ann Neurol        ISSN： 0364-5134            Impact factor:   10.422


  8 in total

Review 1.  A comparative review of the tolerability profiles of dopamine agonists in the treatment of hyperprolactinaemia and inhibition of lactation.

Authors:  J Webster
Journal:  Drug Saf       Date:  1996-04       Impact factor: 5.606

2.  Comparative Review of Dopamine Receptor Agonists in Parkinson's Disease.

Authors:  R J Uitti; J E Ahlskog
Journal:  CNS Drugs       Date:  1996-05       Impact factor: 5.749

Review 3.  Dopamine receptor agonists for the treatment of early or advanced Parkinson's disease.

Authors:  Santiago Perez-Lloret; Olivier Rascol
Journal:  CNS Drugs       Date:  2010-11       Impact factor: 5.749

Review 4.  Current status of dopamine agonists in Parkinson's disease management.

Authors:  J L Montastruc; O Rascol; J M Senard
Journal:  Drugs       Date:  1993-09       Impact factor: 9.546

Review 5.  Cabergoline. A review of its pharmacological properties and therapeutic potential in the treatment of hyperprolactinaemia and inhibition of lactation.

Authors:  C P Rains; H M Bryson; A Fitton
Journal:  Drugs       Date:  1995-02       Impact factor: 9.546

6.  Pleuropulmonary Toxicity of Another Anti-Parkinson's Drug: Cabergoline.

Authors:  Yolanda Belmonte; Oriol de Fàbregues; Marta Marti; Christian Domingo
Journal:  Open Respir Med J       Date:  2009-06-05

Review 7.  Respiratory Dysfunctions in Parkinson's Disease Patients.

Authors:  Any Docu Axelerad; Alina Zorina Stroe; Oana Cristina Arghir; Daniel Docu Axelerad; Anca Elena Gogu
Journal:  Brain Sci       Date:  2021-05-04

8.  Effects of acute administration of DA agonists on locomotor activity: MPTP versus neonatal intracerebroventricular 6-OHDA treatment.

Authors:  Trevor Archer; Tomas Palomo; Robert McArthur; Anders Fredriksson
Journal:  Neurotox Res       Date:  2003       Impact factor: 3.978
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.